CANTON, Mass., Oct. 3 /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC Bulletin Board: - ), developer of the world's first rapid, on-site, fluid-based oral screening test for drugs-of-abuse, recently hosted a roundtable discussion that included contractors, unions, and insurers. The attendees discussed the critical problem of drug abuse in the construction industry and the need for a solution.
"Avitar is pleased to be able to sponsor a national series of forums on drug abuse," said Pete Phildius, CEO of Avitar. "The wealth of expertise expressed by our executive panel members and session attendees truly addressed some of the major issues facing leaders in the construction industry today. Point-of-care (POC) oral fluid-based technology is beginning to be fully recognized as a key element in addressing the growing problem of drug abuse at the workplace."
The event took place on Monday, September 18th in San Francisco, and followed forums in Boston, MA, and Washington, D.C. Attendees discussed the overall importance of random drug testing as a proactive measure to decrease substance abuse related accidents within the construction industry, as well as the positive impacts random drug testing can have on quality of work and productivity. Also noted was the need for uniformity across the sector, so as to prevent drug-users from flocking to those sites that do not test, and thereby creating unsafe work environments.
Panelists included: Alex Stoopenkoff, Corporate Accounts Manager, Pro Trades Connection; John Heil, Safety Director, Kitchell Corporation; and Edward Foust, Sr., Loss Control Consultant, SeaBright Insurance Company.
About Avitar, Inc.
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Its field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen® the world's first non-invasive, rapid, on-site, fluid-based oral screening test for drugs-of-abuse, as well as HYDRASORB®, an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, visit Avitar's Web site at https://avitarinc.com.
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Jay C. Leatherman
The Investor Relations Group